Our laboratory is focused on both fundamental and applied aspects of bacterial bioenergetics and translating this work into the development of new drugs targeting energy generation.
(see http://www.ncbi.nlm.nih.gov/pubmed/25476763)
Current work is also focused on determining the mode of action of new TB drugs against energetic targets including: bedaquiline, Q203 and SQ109.
http://www.ncbi.nlm.nih.gov/pubmed/25754998
http://www.ncbi.nlm.nih.gov/pubmed/25575416
http://www.ncbi.nlm.nih.gov/pubmed/24444429
http://www.ncbi.nlm.nih.gov/pubmed/26593449
http://www.ncbi.nlm.nih.gov/pubmed/25150092
http://www.ncbi.nlm.nih.gov/pubmed/25412183
http://www.ncbi.nlm.nih.gov/pubmed/25118234
http://www.ncbi.nlm.nih.gov/pubmed/26015371
http://www.ncbi.nlm.nih.gov/pubmed/25525207
http://www.ncbi.nlm.nih.gov/pubmed/24936051
Dr Yoshio Nakatani, Research Fellow, yoshio.nakatani@otago.ac.nz
Dr Adam Heikal, Research Fellow, adam.heikal@otago.ac.nz
Dr Yosuke Shimaki, Assistant Research Fellow, yosuke.shimaki@otago.ac.nz
Kiel Hards, PhD candidate, kiel.hards@otago.ac.nz
Jessica Petri, PhD candidate, jessi@kleinvolk.de
Zoe Williams, PhD candidate, zoewilliams@hotmail.co.nz